TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07095127: Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia

Sponsor: Nuvig Therapeutics, Inc. · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 30 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$759,000

Rescue Site Savings

+$517,500

Unlock Full NCT07095127 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07095127 Rescue Dossier →